% IMPORTANT: The following is UTF-8 encoded.  This means that in the presence
% of non-ASCII characters, it will not work with BibTeX 0.99 or older.
% Instead, you should use an up-to-date BibTeX implementation like “bibtex8” or
% “biber”.

@ARTICLE{Packer:124387,
      author       = {R. J. Packer and S. Pfister$^*$ and E. Bouffet and R. Avery
                      and P. Bandopadhayay and M. Bornhorst and D. C. Bowers and
                      D. Ellison and J. Fangusaro and N. Foreman and M. Fouladi
                      and A. Gajjar and D. Haas-Kogan and C. Hawkins and C.-Y. Ho
                      and E. Hwang and N. Jabado and L. B. Kilburn and A.
                      Lassaletta and K. L. Ligon and M. Massimino and S.-v.
                      Meeteren and S. Mueller and T. Nicolaides and G. Perilongo
                      and U. Tabori and G. Vezina and K. Warren and O. Witt$^*$
                      and Y. Zhu and D. Jones$^*$ and M. Kieran},
      title        = {{P}ediatric low-grade gliomas: implications of the biologic
                      era.},
      journal      = {Neuro-Oncology},
      volume       = {19},
      number       = {6},
      issn         = {1523-5866},
      address      = {Oxford},
      publisher    = {Oxford Univ. Press},
      reportid     = {DKFZ-2017-01266},
      pages        = {750-761},
      year         = {2017},
      abstract     = {For the past decade, it has been recognized that pediatric
                      low-grade gliomas (LGGs) and glial-neuronal tumors carry
                      distinct molecular alterations with resultant aberrant
                      intracellular signaling in the Ras-mitogen-activated protein
                      kinase pathway. The conclusions and recommendations of a
                      consensus conference of how best to integrate the growing
                      body of molecular genetic information into tumor
                      classifications and, more importantly, for future treatment
                      of pediatric LGGs are summarized here. There is uniform
                      agreement that molecular characterization must be
                      incorporated into classification and is increasingly
                      critical for appropriate management. Molecular-targeted
                      therapies should be integrated expeditiously, but also
                      carefully into the management of these tumors and success
                      measured not only by radiographic responses or stability,
                      but also by functional outcomes. These trials need to be
                      carried out with the caveat that the long-term impact of
                      molecularly targeted therapy on the developing nervous
                      system, especially with long duration treatment, is
                      essentially unknown.},
      subtyp        = {Review Article},
      cin          = {B062 / G340},
      ddc          = {610},
      cid          = {I:(DE-He78)B062-20160331 / I:(DE-He78)G340-20160331},
      pnm          = {312 - Functional and structural genomics (POF3-312)},
      pid          = {G:(DE-HGF)POF3-312},
      typ          = {PUB:(DE-HGF)16},
      pubmed       = {pmid:27683733},
      pmc          = {pmc:PMC5464436},
      doi          = {10.1093/neuonc/now209},
      url          = {https://inrepo02.dkfz.de/record/124387},
}